Imperial College London
Professor Robert Wilkinson

ProfessorRobertWilkinson

Faculty of Medicine, Department of Infectious Disease

Professor in Infectious Diseases
 
 
 
//

Contact

 

r.j.wilkinson Website

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{van:2022:10.1038/s41598-022-06221-8,
author = {van, den Berg K and Glatt, TN and Vermeulen, M and Little, F and Swanevelder, R and Barrett, C and Court, R and Bremner, M and Nyoni, C and Swarts, A and Mmenu, C and Crede, T and Kritzinger, G and Naude, J and Szymanski, P and Cowley, J and Moyo-Gwete, T and Moore, PL and Black, J and Singh, J and Bhiman, JN and Baijnath, P and Mody, P and Malherbe, J and Potgieter, S and van, Vuuren C and Maasdorp, S and Wilkinson, RJ and Louw, VJ and Wasserman, S},
doi = {10.1038/s41598-022-06221-8},
journal = {Scientific Reports},
title = {Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)},
url = {http://dx.doi.org/10.1038/s41598-022-06221-8},
volume = {12},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background:There is a need for effective therapy for COVID-19 pneumonia. Convalescent plasma has antiviral activity and early observational studies suggested benefit in reducing COVID-19 severity. We investigated the safety and efficacy of convalescent plasma in hospitalized patients with COVID-19 in a population with a high HIV prevalence and where few therapeutic options were available.Methods:We performed a double-blinded, multicenter, randomized controlled trial in one private and three public sector hospitals in South Africa. Adult participants with COVID-19 pneumonia requiring non-invasive oxygenwere randomized 1:1 to receive a single transfusion of 200mL of either convalescent plasma or 0.9% saline solution. The primary outcome measure was hospital discharge and/or improvement of ≥ 2 points on theWorld Health Organisation Blueprint Ordinal Scale for Clinical improvement by day 28 of enrolment. The trialwas stopped early for futility by the Data and Safety Monitoring Board.Results:103 participants, including 21 HIV positive individuals, were randomized at the time of premature trial termination: 52 in the convalescent plasma and 51 in the placebo group. The primary outcome occurred in 31 participants in the convalescent plasma group and and 32 participants in the placebo group (relative risk 1.03 (95% CI, 0.77 to 1.38). Two grade 1 transfusion-related adverse events occurred. Participants who improved clinically received convalescent plasma with a higher median anti-SARS-CoV-2 neutralizing antibody titre compared with those who did not (298 versus 205 AU/mL).Conclusions:Our study contributes additional evidence for recommendations against the use of convalescent plasma for COVID-19 pneumonia. Safety and feasibility in this population supports future investigation for otherindications.
AU  - van,den Berg K
AU  - Glatt,TN
AU  - Vermeulen,M
AU  - Little,F
AU  - Swanevelder,R
AU  - Barrett,C
AU  - Court,R
AU  - Bremner,M
AU  - Nyoni,C
AU  - Swarts,A
AU  - Mmenu,C
AU  - Crede,T
AU  - Kritzinger,G
AU  - Naude,J
AU  - Szymanski,P
AU  - Cowley,J
AU  - Moyo-Gwete,T
AU  - Moore,PL
AU  - Black,J
AU  - Singh,J
AU  - Bhiman,JN
AU  - Baijnath,P
AU  - Mody,P
AU  - Malherbe,J
AU  - Potgieter,S
AU  - van,Vuuren C
AU  - Maasdorp,S
AU  - Wilkinson,RJ
AU  - Louw,VJ
AU  - Wasserman,S
DO  - 10.1038/s41598-022-06221-8
PY  - 2022///
SN  - 2045-2322
TI  - Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)
T2  - Scientific Reports
UR  - http://dx.doi.org/10.1038/s41598-022-06221-8
UR  - https://www.nature.com/articles/s41598-022-06221-8
UR  - http://hdl.handle.net/10044/1/94025
VL  - 12
ER  -
Download